Analytical Services Center for Medications Development Program

药物开发计划分析服务中心

• 批准号: 8890008
• 负责人: YONG HUANG
• 金额: $ 53.26万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2018-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8890008
• 关键词: Archives; Biological; Biological Assay; Biological Markers; Chemistry; Clinical; Clinical Trials; Cocaine; Collection; Contractor; Contracts; Data; Databases; Development; Devices; Drug Addiction; Drug Kinetics; Drug user; Electronics; Hair; Illicit Drugs; Label; Laboratories; Methamphetamine; Molecular; Naltrexone; National Institute of Drug Abuse; Outcome Measure; Peptides; Pharmaceutical Preparations; Plasma; Program Development; Proteins; Records; Reporting; Resources; Saliva; Sampling; Secure; Services; Site; Substance Abuse Detection; Urine; analytical method; clinical research site; data management; drug of abuse; drug testing; pre-clinical; research and development; sample collection; screening; small molecule; therapy development; treatment program

The objective of Task A is to develop and validate analytical methods to quantify new medications, metabolites, illicit drugs and endogenous biomarkers in plasma, urine and other biological matrices. The validated assays will be used for preclinical and clinical pharmacokinetic (PK) studies in order to support NIDA's medications development programs. The objective of Task B is to quantify a variety of compounds including new medications, their metabolites, illicit drugs and endogenous substances or biomarkers in plasma/serum, urine and other biological matrices, such as saliva or hair. The compounds to be quantified include, but are not limited to, the following drugs and their metabolites: cocaine, methamphetamine, naltrexone, and other potential medications under development, such as GSK 598809. Task C: One important aspect of medication development for treatment of abused drug addiction involves identifying the drug user by screening urine samples and the assessment of the medication in reducing the use of the target abused drug by participating subjects. This clinical outcome measure requires assay of urine samples for the abused drugs and their metabolites. This task can be divided into two parts: a) urine abused drug screening; and b) urine abused drug confirmatory/quantitative analysis. Task D: On-site drug testing devices can quickly identify the drug user and the common abused drugs. To support the clinical trial for abused drug treatment program, the Contractor will purchase and distribute 4-9 multi-panel urine on-site drug testing devices to each clinical site. Task E: Clinical trials for drug addiction treatment require collection of biological samples for analysis. To provide such services, the Contractor will purchase and supply all necessary sample collection and shipment containers, sample labels and shipment cartons, etc. to each clinical site. Task F: The Contractor shall prepare and maintain all assay results in electronic files for submission to NIDA with corresponding reports and for submission to the data management centers designated by NIDA. The objective of Task G is to archive and maintain all records, which includes laboratory notebooks, hard copies of raw data, and databases of assay results on disk in secure storage for a period up to 5 years in case a GLP audit is required by FDA in connection with an IND or NDA submission.

任务A的目的是开发和验证分析方法，以量化血浆，尿液和其他生物基质中的新药物，代谢产物，非法药物和内源性生物标志物。经过验证的测定法将用于临床前和临床药代动力学（PK）研究，以支持NIDA的药物开发计划。 任务B的目的是量化各种化合物，包括新药物，其代谢产物，非法药物和内源性物质或血浆/血清中的生物标志物，尿液和其他生物基质（例如唾液或头发）。要量化的化合物包括但不限于以下药物及其代谢产物：可卡因，甲基苯丙胺，纳曲酮和其他正在开发的潜在药物，例如GSK 598809。 任务C：治疗滥用药物成瘾的药物开发的一个重要方面是通过筛查尿液样本来识别药物使用者，并评估药物在减少靶标滥用药物的使用时通过参与受试者的使用。这种临床结果指标需要对滥用药物及其代谢产物的尿液样品进行测定。该任务可以分为两个部分：a）滥用尿液的药物筛查； b）尿液滥用药物验证性/定量分析。 任务D：现场药物测试设备可以迅速识别吸毒者和普通滥用药物。为了支持滥用药物治疗计划的临床试验，承包商将向每个临床部位购买和分发4-9个多面板尿现场药物测试设备。 任务E：药物成瘾治疗的临床试验需要收集生物样品进行分析。为了提供此类服务，承包商将向每个临床站点购买和提供所有必要的样品收集和装运容器，样品标签和装运纸箱等。 任务F：承包商应在电子文件中准备并维护所有测定结果，并通过相应的报告提交给NIDA，并提交给NIDA指定的数据管理中心。 任务G的目的是归档和维护所有记录，其中包括实验室笔记本，原始数据的硬副本以及在安全存储中的磁盘上的测定结果结果，以防FDA与IND或NDA提交有关的FDA需要进行GLP审核。